Bio-Rad Laboratories

Phase A — Understand the business

Lens 1 · Company Overview

Bio-Rad is a 1952-founded (David & Alice Schwartz), Hercules CA-headquartered manufacturer and global distributor of its own life-science research and clinical-diagnostics products — ~7,450 employees in 37 countries, >12,000 SKUs. Two reportable segments:

• Clinical Diagnostics (~60% of sales) — diagnostic test systems, quality controls, blood typing, diabetes (HbA1c) testing, informatics, sold to hospital/reference/transfusion/physician-office labs. Regulated as medical devices (FDA + ex-US). This is the steadier, reimbursement-exposed franchise. FY2025 sales $1,562.1M.
• Life Science (~40% of sales) — instruments/reagents/consumables to separate, purify, characterize and quantify cells, proteins and nucleic acids: ddPCR/qPCR (Droplet Digital PCR), Western blotting, chromatography, cell biology, process chromatography for biopharma manufacturing, food-safety testing. Customers = universities, gov agencies, pharma/biotech, food producers. FY2025 sales $1,021.1M.

Revenue model: ~97% product/consumable/service sales; ~3% is reagent-rental lease revenue (razor-and-blade instrument placements). Recurring consumables/QC pull-through is the quality of the franchise; instrument capital sales are the cyclical part that has been hit.

The defining feature, not a footnote: Bio-Rad owns 12,987,900 ordinary voting + 9,588,908 preference shares of Sartorius AG (~38% of ordinary ex-treasury, ~28% of preference), fair value $5,669.2M at 12/31/2025. It is marked to market through the P&L (not equity-method), so reported net income is dominated by Sartorius's share price, independent of operating performance. Plus a €400M collateralized loan to a Sartorius-family entity (SHB) maturing Jan 2029, carrying value appreciation rights convertible into Sartorius ordinary shares when the family trust terminates mid-2028.

Governance: dual-class (Class A = 1/10 vote, Class B = 1 vote); the Schwartz family controls a majority of voting power and elects a majority of the board. CEO/Chairman Norman Schwartz (founder's son). Director Allison Schwartz also on the board.

Lens 2 · Supply Chain

Inputs → Bio-Rad → end customer:

• Upstream: antibodies/antigens, enzymes & polymerases, oligonucleotides, microfluidic/droplet chemistry, optics & instrument electronics, plastics/consumables resin, and reagent raw materials. Goods are manufactured in a small number of locations then shipped to local distribution hubs worldwide. Manufacturing concentrated in US, France, Germany, Switzerland, with EU operations material (Europe = $187.6M of long-lived assets).
• Bio-Rad itself: vertically integrated developer-manufacturer (it sells "its own" products — limited reliance on third-party finished goods). FDA/ISO 13485/MDSAP-inspected facilities for the diagnostics side.
• Downstream / named end buyers: universities & medical schools, government agencies (NIH-grant-funded labs — a key demand driver), pharma & biotech manufacturers, food producers/testing labs (Life Science); hospital labs, diagnostic reference labs, blood-transfusion labs, physician-office labs (Clinical Diagnostics).
• Chokepoints / single-source: the filing flags supply-chain risk generically; the more specific exposures are (1) EMEA logistics — the Middle East conflict disrupted Diagnostics shipments into EMEA in Q1 2026 and is expected to persist through 2026 (EMEA Diagnostics >9% of segment); (2) FX-denominated cost base — ~60% of sales and a large share of costs are non-USD (Euro, CHF, JPY, CNY, GBP), so a strong dollar compresses reported sales while a weak dollar inflates ex-US costs; (3) tariffs / trade barriers explicitly named as a 2026 risk.

This is a low single-source-risk, self-manufactured chain — the vulnerability is demand (academic funding) and FX/logistics, not a fragile upstream node.

Lens 3 · Competitive Advantages (moats)

• Installed base + consumable lock-in (real but mid-tier). Reagent-rental instrument placements and proprietary QC/consumables create switching costs once a lab standardizes a workflow (blood typing, HbA1c QC, ddPCR assays). ~3% lease revenue understates the consumable pull-through. This is the durable part.
• Quality-control / blood-typing franchise (strong niche). Bio-Rad is a leader in clinical QC and blood typing — sticky, regulated, recurring, less cyclical. FY2025 Diagnostics growth was "primarily driven by quality control and blood typing".
• Breadth, not depth. Management's own framing: the Life Science portfolio is so broad ("thousands of products") that no single competitor faces it across the board. Breadth is a distribution/cross-sell asset but not a pricing moat — in each product line Bio-Rad faces a scale leader.
• Bargaining power: weak-to-neutral. Against customers: academic/gov buyers are price- and budget-constrained (grant-dependent), and diagnostics is reimbursement-capped (China diabetes reimbursement cuts hit 2025). Against suppliers: no disclosed leverage. Bio-Rad is a price-taker in a market dominated by Danaher and Thermo Fisher.
• The "hidden moat" that isn't operational: the Sartorius stake. It is a financial asset, not a competitive advantage — but it is the single largest driver of the equity's value (see Lens 11/12).

Net: a respectable, defensible #3–#5 player with sticky diagnostics QC, but no scale, process (Danaher Business System), or network moat to compound margins. Operating margin tells the story — see Lens 4/5.

Lens 4 · Segments

Hard, from the segment note:

Trend & cause:

• Life Science is in a multi-year contraction: −13% from FY2023 to FY2025 ($1,178M → $1,021M), as the post-COVID + academic/biotech funding downturn crushed instrument and ddPCR/qPCR/Western-blot demand. Currency-neutral LS −1.3% in FY2025, −4.3% in Q1 2026.
• Clinical Diagnostics has been the ballast: +1.6% reported FY2025, driven by QC + blood typing, offset by lower China diabetes reimbursement. But it turned −4.1% currency-neutral in Q1 2026 on the Middle East/EMEA disruption — so even the steady leg is now soft.
• Geographic: US $1,022.7M, Europe $881.8M, Asia $513.3M, Other $165.4M (FY2025). ~40% US / ~60% international. Q1 2026: US $229.8M, EMEA $206.8M, APAC $110.4M.

The segment data confirms the thesis: a shrinking-to-flat, low-margin operating business where the only growth is bolt-on M&A (Stilla) and the only stability is recurring diagnostics QC.

---

Phase B — Measure performance

Lens 5 · Earnings Result (most recent print: Q1 2026, reported 2026-04-30)

Consolidated income statement, Q1 2026 vs Q1 2025:

• Revenue: +1.1% reported but −4.2% currency-neutral — i.e. the underlying business shrank ~4%; the print was only positive because of a weak dollar. Came in light vs ~$594.8M consensus. Both segments down CN (LS −4.3%, CDx −4.1%).
• EPS: non-GAAP $1.89 beat the $1.84 whisper but missed the ~$2.00 consensus; the GAAP $(19.55) is pure Sartorius mark-to-market noise (a $727.7M Sartorius loss inside the $738.2M line).
• Guidance — cut, twice over: FY2026 CN revenue revised to −3.0% to +0.5% (from +0.5% to +1.5%); FY2026 non-GAAP operating margin to ~10.0%–12.0% (from ~12.0%–12.5%). Management cited the Middle East conflict (>9% of Diagnostics) as a persistent 2026 headwind.
• Balance-sheet flags: inventory $740.7M (high vs ~$2.58B sales — ~106 days COGS); deferred-tax valuation allowance increased $8.8M in Q1 on "objectively verifiable negative evidence" about DTA realization — a quiet tell on the operating earnings trajectory. Operating cash flow fell to $108.1M.
• Market reaction: stock was already ~$275 around the print (had fallen from a 2021 high of $825); the real move came three weeks later on Elliott (Lens 8).
• Unusual vs own history: FY2025 included $172.8M of IPR&D impairments (Dropworks $81.7M + Curiosity $91.1M net), which collapsed FY2025 GAAP operating income to $47.2M (from $269.0M FY2024, $337.8M FY2023). Underlying (ex-impairment) operating income ~$220M, ~8.5% margin — structurally low for the sector.

Lens 6 · Earnings Calls (sentiment trend)

transcripts/ is empty (n/a — research-layer); sentiment is from web summaries.

• FY2023/2024 calls: defensive — "headwinds," "cautious 2024 growth," broad-based Life Science declines (ddPCR/qPCR/Western down ~19% in Q4'23).
• FY2025 → Q1 2026: tone shifted from "stabilizing / recovery in H2" to "idiosyncratic product headwinds in 2026, recovery deferred to 2027" — management has been pushing the recovery out. Q1 2026 call added the Middle East/EMEA disruption and a guidance cut, while leaning on digital PCR (Stilla) as the strategic bright spot.
• Recurring phrases: "currency-neutral," "constrained academic/biotech funding," "bolt-on," "operating-margin improvement program," "restructuring." Stopped saying: confident near-term organic-growth reacceleration.
• Net sentiment: deteriorating/defensive, with the narrative increasingly about cost-out (restructuring $48.9M in 2025) and portfolio focus rather than top-line growth.

Lens 7 · Comps

Life-science-tools + diagnostics peers. Multiples are ``, dated June 2026 (sources: stockanalysis.com, Yahoo, gurufocus, koalagains). 5-yr avg ROE not cleanly sourced for the set → n/a.

Read: On a consolidated EV/EBITDA (~16.8x) Bio-Rad screens roughly in line to slightly cheap vs A/RVTY (18x) and rich vs QGEN (12.5x). But the consolidated multiple is meaningless because EV ($7.23B) is smaller than the Sartorius stake ($5.0–5.7B). The honest comp is a sum-of-the-parts: strip the ~$5B Sartorius stake (less ~$1.2B debt + tax leakage) and the operating business is implied at only ~$2.3–3.0B EV, i.e. ~1x sales — a deep discount to every tools peer, which is precisely the gap Elliott is attacking (Lens 8/12). The fwd P/E of ~27x is the trap: it looks expensive only because operating margin (~10–12%) is depressed; on the asset value the stock is cheap.

Lens 8 · Stock-Price Catalysts (>5% moves, ~5 yrs)

• Sep 2021 — all-time high $825.77. Peak coincided with COVID-era PCR/diagnostics demand and a near-peak Sartorius share price (the stake was worth far more then).
• 2022–2024 — secular de-rate from ~$800 → ~$300: post-COVID PCR normalization + the academic/biotech funding drought (NIH grant delays/cuts — grants ran ~1,189 vs ~2,322 YoY) gutted Life Science; simultaneously Sartorius shares fell hard (FY2024 alone: a $2.68B holding loss on Sartorius). The stock is a levered play on two things falling together.
• Each Q earnings: moves driven by currency-neutral organic growth vs guide and Sartorius mark — the GAAP EPS is ignored; the market trades the organic number + the stake.
• 2026-04-30 (Q1 print + guide cut): modest (~+1.8% AH to ~$275) — the beat-on-EPS cushioned the revenue miss/guide-down.
• 2026-05-18 — Elliott Investment Management discloses activist stake → stock surged ~11%. THE catalyst of the year. Elliott's thesis: the market values Bio-Rad at ≈ the Sartorius stake alone, so the operating business is "free"; push to (a) monetize/credit the ~$5B Sartorius position and (b) fix operating margins.

Pattern: the market reacts to (1) the Sartorius share price, (2) organic-growth-vs-guide, and now (3) the activist value-unlock path. It does not care about reported GAAP EPS. This is a special-situation/SOTP name.

---

Phase C — Judge people & books

Lens 9 · Management

• Track record (mixed-to-poor on value creation). Norman Schwartz — CEO since 2003 (~23 yrs), with Bio-Rad since 1995, Chairman since ~2012; founder's son. Long tenure, deep domain credibility, patient R&D culture. But the stock is −64% from its 2021 peak and operating margins have eroded to ~8–12%; the family's "patient compounder" framing has produced a structurally sub-scale, low-margin operator that the market values below its passive Sartorius stake. CFO Roop K. Lakkaraju joined Feb 2024 (relatively new).
• Skin in the game (high — and the double-edge). Schwartz family controls a majority of voting power via Class B dual-class. Enormous alignment by ownership, but it entrenches management and blocks a change of control — the core governance objection an activist faces.
• Capital-allocation history (the crux). Conservative leverage (investment-grade, $1.2B fixed-rate notes), steady buybacks (FY2025 repurchased 1.2M Class-A shares for $295.5M; $284.6M left on the program). M&A has been serial bolt-on (AbD Serotec, GnuBIO, Dropworks, Curiosity, Stilla $257.7M in 2025) — but two of those just produced $172.8M of IPR&D impairments (Dropworks delayed/abandoned, Curiosity discontinued). The single biggest capital-allocation question is the unmanaged ~$5B Sartorius position: held passively, marked to market, no board seat (management "tried and failed" to get equity-method access). Decades of not monetizing or de-risking it is what Elliott is now challenging.
• Red flags. Family on both sides of the board (Norman + Allison Schwartz); dual-class entrenchment; related-party-flavored €400M loan to a Sartorius-family entity (arm's-length-priced at 1.5%, collateralized, with value-appreciation rights). Comp specifics are in the proxy (not on shelf) → n/a — not on shelf.
• Archetype: founder-family steward, not an operator-allocator. Implication: durable, conservative, but value-creation has lagged badly — exactly the profile activists target. Whether Schwartz family control bends to Elliott is the swing factor.

Lens 10 · Forensic Red Flags

Forensic lens — every figure labeled.

• GAAP earnings are non-economic. Reported net income is dominated by the Sartorius mark (+$900.4M FY2025 gain; −$2,656.8M FY2024; −$1,252.3M FY2023; −$738.2M Q1 2026). Never use GAAP EPS for this name — back it out and look at segment gross profit, operating income ex-impairment, and FCF. Not a fraud risk; a reading risk.
• Impairments / M&A quality. $172.8M IPR&D impairment in FY2025 (Dropworks + Curiosity) signals over-paid / over-optimistic acquisitions in ddPCR/molecular. Goodwill rose to $579.8M (Stilla added $160.5M) — watch for the next impairment if Stilla's ddPCR ramp disappoints. Stilla contingent consideration up to $50M (fair value ~$29.7M).
• Cash flow vs earnings. Operating CF $532.2M FY2025 is real and healthy vs ~$220M underlying operating income — D&A ($165M) + the non-cash Sartorius line reconcile it. No divergence concern; OCF quality is fine.
• Working capital. Inventory $740.7M (~106 days) is elevated and ticked up in Q1 2026 (+$29.9M) — a yellow flag in a shrinking-revenue environment; receivables in line. One-time inventory write-offs already hit Life Science GM in FY2025.
• Deferred-tax valuation allowance increased on negative evidence — corroborates weak forward operating earnings.
• SBC: ~$15.0M/qtr, modest (~2.5% of sales) — non-GAAP is not heavily SBC-flattered.
• Investment Company Act risk (structural): because the Sartorius stake is so large relative to the operating business, Bio-Rad explicitly discloses it could be deemed an "investment company" under the '40 Act and relies on a Section 3(b)(1) exemption. A real, if remote, structural tail-risk — and an argument for monetizing the stake.

Regulatory findings:

• SEC Litigation Releases: none for Bio-Rad in 2021-06-30→2026-06-30.
• AAERs: none in period.
• 10-K Item 3 / Note 15 (Legal Proceedings): "party to various claims, legal actions and complaints arising in the ordinary course of business… we do not believe… any ultimate liability… will have a material adverse effect" — no material litigation disclosed.
• Non-SEC (web search — FTC/DOJ/FDA/penalties): no material new enforcement surfaced in this pass for the current period. Historical note for context: Bio-Rad settled an FCPA matter with the SEC/DOJ in 2014 (~$55M, Russia/Vietnam/Thailand) — well outside the 5-yr window and not in current filings; flag only as legacy. No current consent decree found.
• Conclusion: No material current regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), 10-K Item 3/Note 15, and web search as of 2026-06-30. Accounting controls: KPMG unqualified opinion on financials and ICFR; auditor since 2013; critical audit matter = sufficiency of audit evidence over net sales (scope/dispersion, not a misstatement flag).

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

Built bottom-up from FY2025 actuals + the cut FY2026 guide. GAAP EPS is un-forecastable (it's the Sartorius mark) — so the operating projection is on non-GAAP operating EPS (ex-Sartorius), which is what the business is worth. Every line labeled; output ``.

Anchors: FY2025 sales $2,583.2M; underlying operating margin ~8.5% GAAP (12% non-GAAP pre-impairment); FY2026 guide CN revenue −3.0% to +0.5%, non-GAAP op-margin 10–12%. Consensus non-GAAP EPS 2026 has been cut into the **$8.3–$10.3** range. Diluted shares ~26.96M and falling on buybacks.

The EPS is the less important axis. For this name the value driver is the sum-of-the-parts: Sartorius stake ~$5.0–5.7B + operating business (even at a conservative ~12x EBIT on ~$280M = ~$3.4B) − net debt ~$0.7B − tax leakage on the stake ⇒ a fair SOTP well north of today's ~$7.95B market cap, with the gap entirely about the Sartorius discount + the operating-margin recovery.

Brier forecast not logged (watchlist breadth rule — skip forecast.ts create; no committed base case in unattended mode). If logged later, the scoreable base would be: "BIO FY2026 non-GAAP EPS ≥ $9.00, p≈0.55, resolves 2027-02".

Lens 12 · Bull vs Bear

Bull case. This is a $5B Sartorius stake with a free-ish operating call option, and an activist now holding the unlock key. At ~$7.95B market cap the market is paying ≈ the Sartorius stake and ascribing almost nothing to a $2.58B-revenue, gross-profit-$1.34B franchise with sticky diagnostics QC/blood-typing. Three levers: (1) Elliott (disclosed 5/18/26) forces monetization/credit of Sartorius and/or governance change — a hard re-rate catalyst independent of the P&L; (2) operating-margin self-help — restructuring + portfolio focus lifts non-GAAP op-margin from ~11% toward the mid-teens (peers run 20%+), each 100bps ≈ ~$0.9 EPS; (3) 2027 academic-funding normalization + Stilla ddPCR re-accelerates Life Science. Downside is cushioned by the asset value. Pre-mortem-positive: even if the business stays mediocre, the SOTP floor limits the loss.

Bear case. (1) The Sartorius discount is structural, not temporary — Bio-Rad has no control (no board seat, "tried and failed" for equity-method access), the Sartorius family trust holds the majority of ordinary shares, and Bio-Rad can't freely sell ~38% of a foreign listco without crushing the price or triggering tax. Elliott can shout, but the family-on-family lock (Schwartz controls BIO, Sartorius family controls Sartorius) may make the discount permanent. (2) The operating business is in secular decline — Life Science −13% over two years, Diagnostics now also negative CN, margins ~8–12% structurally below peers, two recent M&A write-offs. (3) Expectations: the SOTP "free option" is already partly priced after the +11% Elliott pop; if Sartorius shares fall, the entire equity falls regardless of operations. Pre-mortem (18 mo out, thesis broke): Elliott settles for a board seat and buyback with no Sartorius monetization; academic funding stays frozen into 2027; Sartorius shares de-rate another 20% → the stake shrinks to ~$4B, BIO drifts back toward ~$250 and the SOTP "floor" proves soft.

Are multiples too high? Consolidated fwd P/E ~27x looks high but is an artifact of depressed margins; the asset-based view is cheap. The risk isn't the multiple — it's whether the discount ever closes.

Contrarian view (what the market refuses to see): The market is debating "life-science-tools recovery timing." The real question is corporate-structure: Bio-Rad is a closed-end-fund-like holding company trading at a wide discount to NAV, and the variable that matters is not NIH funding but whether Schwartz-family control yields to Elliott. Most tools-sector analysts are mis-framing it as an operating story.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• The "free operating business" is worth less than bulls claim. Sub-scale, ~10–12% margins, shrinking, two recent IPR&D write-offs — at a fair ~10–12x EBIT it's ~$2.8–3.4B, not the ~$5B+ bulls imply. The "discount" is partly deserved: a low-quality operator stapled to an illiquid foreign minority stake should trade below NAV.
• Concentration / structural break: revenue is geographically dispersed (fine), but the equity's value is ~60–70% one line item — Sartorius shares Bio-Rad can't control or easily sell. If Sartorius de-rates (it already cost Bio-Rad $2.68B in FY2024 alone), the stock breaks regardless of operations. That's the single scenario that permanently impairs the equity (not the business): a sustained Sartorius drawdown + a frozen trust = a discount that never closes.
• Most dangerous competitor bulls underestimate: Thermo Fisher + Danaher in ddPCR/qPCR and diagnostics — they out-R&D, out-distribute, and out-price Bio-Rad. Stilla buys share in digital PCR but the whole PCR category is post-COVID deflating; Bio-Rad is consolidating a shrinking niche.
• Worst capital-allocation moves: decades of holding a passive, uncontrollable ~$5B stake instead of monetizing/hedging it; over-paid ddPCR M&A (Dropworks/Curiosity → $172.8M impaired); a related-party €400M loan to the Sartorius family.
• What must hold for today's price: that either Elliott forces a Sartorius monetization or the operating business re-accelerates in 2027 and Sartorius shares don't fall. If 20–30% of expected growth evaporates and Sartorius is flat-to-down, fair value is closer to ~$240–260 — the activist pop unwinds.
• Plausibility of the permanent-impairment scenario: moderate. The family-on-family control lock is real; Elliott's leverage against a dual-class founder-controlled company is weaker than usual.

Lens 14 · Management Questions (ordered by information value)

1. What is the board's actual plan for the ~$5B Sartorius stake — monetize, hedge, distribute, or hold — and what specifically changed in that posture after Elliott's May 18 filing?
2. Given you have no Sartorius board seat and "tried and failed" to obtain equity-method access, what realistic paths exist to crystallize the stake's value without triggering punitive tax or a forced-seller discount?
3. Will the Schwartz family support a change-of-control or a structural separation if that maximizes shareholder value, or is dual-class control a hard constraint Elliott cannot move?
4. What is the bridge from ~11% to mid-teens non-GAAP operating margin, by year, and how much is structural vs cyclical-funding-dependent?
5. What gives you confidence in a 2027 academic/biotech funding recovery rather than a permanently lower NIH-funded demand baseline?
6. After $172.8M of IPR&D impairments (Dropworks, Curiosity), what has changed in M&A diligence and hurdle rates — and is Stilla at risk of the same write-off?
7. How big can digital PCR (Stilla) realistically be, against Thermo/QuantStudio and a deflating post-COVID PCR market, and what's the path to the $50M earn-out?
8. What is the durable trajectory of the Clinical Diagnostics QC/blood-typing franchise now that it has also turned negative currency-neutral (EMEA/Middle East)?
9. Why hold $1.5B in cash + short-term investments and $1.2B debt rather than aggressively buying back the stock at a discount to SOTP NAV?
10. What is the tax basis and structure of the Sartorius position, and what is the after-tax net to shareholders under each monetization scenario?
11. How do you think about the '40 Act "investment company" risk — does it actually force a reduction in the Sartorius stake at some threshold?
12. What are the terms/exit on the €400M SHB loan + value-appreciation rights when the trust terminates mid-2028 — does Bio-Rad end up owning more Sartorius, and is that the intended direction?
13. What is the China diabetes-reimbursement outlook and broader China exposure for Diagnostics?
14. Where is pricing power still real across the portfolio, and where are you a price-taker to Danaher/Thermo?
15. What would make the board walk away from the operating business entirely (sell it, become a pure Sartorius holdco) — is that on the table?

---